COVID Update: Masks are still required in health care settings, even if you’re fully vaccinated. Also, Scripps does not provide COVID-19 tests for asymptomatic patients. See FAQs.

Investigational cell therapy to prevent rejection of a transplanted kidney

Trial ID:
IRB-20-7493
Christopher Marsh, M.D.
This is a randomized trial to evaluate the safety and effectiveness of a investigational stem-cell based therapy compared to standard anti-rejection treatment in living donor renal transplant patients. All surgery, procedures and treatments will take place at Scripps Clinic/ Green Hospital Torrey Pines.

Inclusion Criteria

Patients must:
  • • Be at least 18 years old
  • • Be clinically indicated for a kidney transplant
  • • Have identified a suitable living kidney donor between ages 18-60
  • • Must qualify for kidney transplant through our Solid Organ Transplant Department
  • • Meet additional criteria

Exclusion Criteria

Patients must not:
  • • Have a BMI >35
  • • Be a biologically unrelated female donor to male recipient
  • • Have had a previous transplant

Additional Info

  • FREEDOM-1 is exploring the use an investigational cell therapy comprised of stem cells, which are immature cells, obtained from a living donor to prevent rejection after a kidney transplant. Patients will be randomized to receive the investigational therapy or standard anti-rejection treatment. Total study duration is expected to be about 5 years. Travel reimbursement is provided.
  • Search for NCT 03995901 at www.clinicaltrials.gov for more information

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org